Introduction: Gestational diabetes mellitus (GDM) is the most frequent metabolic complication during pregnancy and is associated with development of short-term and long-term complications for newborns, with large-for-gestational-age (LGA) being particularly common. Interestingly, the mechanism behind altered fetal growth in GDM is only partially understood. Research design and methods: A proteomic approach was used to analyze placental samples obtained from healthy pregnant women (n=5), patients with GDM (n=12) and with GDM and LGA (n=5). Effects of altered proteins on fetal development were tested in vitro in human embryonic stem cells (hESCs). Results: Here, we demonstrate that the placental proteome is altered in pregnant women affected by GDM with LGA, with at least 37 proteins differentially expressed to a higher degree (p<0.05) as compared with those with GDM but without LGA. Among these proteins, 10 are involved in regulating tissue differentiation and/or fetal growth and development, with bone marrow proteoglycan (PRG2) and dipeptidyl peptidase-4 (DPP-4) being highly expressed. Both PRG2 and DPP-4 altered the transcriptome profile of stem cells differentiation markers when tested in vitro in hESCs, suggesting a potential role in the onset of fetal abnormalities. Conclusions: Our findings suggest that placental dysfunction may be directly responsible for abnormal fetal growth/development during GDM. Once established on a larger population, inhibitors of the pathways involving those altered factors may be tested in conditions such as GDM and LGA, in which therapeutic approaches are still lacking.

Placental proteome abnormalities in women with gestational diabetes and large-for-gestational-age newborns / E. Assi, F. D'Addio, C. Mandò, A. Maestroni, C. Loretelli, M. Ben Nasr, V. Usuelli, A. Abdelsalam, A.J. Seelam, I. Pastore, C. Magagnotti, R. Abdi, B. El Essawy, F. Folli, D. Corradi, G. Zuccotti, I. Cetin, P. Fiorina. - In: BMJ OPEN DIABETES RESEARCH AND CARE. - ISSN 2052-4897. - 8:2(2020 Nov 01). [10.1136/bmjdrc-2020-001586]

Placental proteome abnormalities in women with gestational diabetes and large-for-gestational-age newborns

E. Assi
Primo
;
F. D'Addio
Secondo
;
C. Mandò;A. Maestroni;C. Loretelli;M. Ben Nasr;V. Usuelli;A. Abdelsalam;A.J. Seelam;I. Pastore;F. Folli
Writing – Review & Editing
;
G. Zuccotti;I. Cetin
Penultimo
;
P. Fiorina
Ultimo
2020

Abstract

Introduction: Gestational diabetes mellitus (GDM) is the most frequent metabolic complication during pregnancy and is associated with development of short-term and long-term complications for newborns, with large-for-gestational-age (LGA) being particularly common. Interestingly, the mechanism behind altered fetal growth in GDM is only partially understood. Research design and methods: A proteomic approach was used to analyze placental samples obtained from healthy pregnant women (n=5), patients with GDM (n=12) and with GDM and LGA (n=5). Effects of altered proteins on fetal development were tested in vitro in human embryonic stem cells (hESCs). Results: Here, we demonstrate that the placental proteome is altered in pregnant women affected by GDM with LGA, with at least 37 proteins differentially expressed to a higher degree (p<0.05) as compared with those with GDM but without LGA. Among these proteins, 10 are involved in regulating tissue differentiation and/or fetal growth and development, with bone marrow proteoglycan (PRG2) and dipeptidyl peptidase-4 (DPP-4) being highly expressed. Both PRG2 and DPP-4 altered the transcriptome profile of stem cells differentiation markers when tested in vitro in hESCs, suggesting a potential role in the onset of fetal abnormalities. Conclusions: Our findings suggest that placental dysfunction may be directly responsible for abnormal fetal growth/development during GDM. Once established on a larger population, inhibitors of the pathways involving those altered factors may be tested in conditions such as GDM and LGA, in which therapeutic approaches are still lacking.
diabetes; gestational; placenta; proteomics;
Settore MED/09 - Medicina Interna
1-nov-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
e001586.full(1).pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 993.55 kB
Formato Adobe PDF
993.55 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/789160
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact